key: cord-1040392-qb06fomc authors: Niebel, Dennis; Wilhelmi, Jasmin; De Vos, Luka; Ziob, Jana; Jaschke, Kristel; Bieber, Thomas; Wenzel, Joerg; Braegelmann, Christine title: Annular plaques mimicking Rowell’s syndrome in the course of coronavirus disease 2019 mRNA vaccines: An overlooked phenomenon? date: 2021-10-24 journal: J Dermatol DOI: 10.1111/1346-8138.16210 sha: 45664711d4af37bc2ff1b1baa5924a3f141ea642 doc_id: 1040392 cord_uid: qb06fomc Effective vaccines for prevention of severe course and lethal outcome of coronavirus disease 2019 have been developed and approved in regulatory rolling and fast‐track procedures; they are now widely distributed worldwide. Data about cutaneous side‐effects of the new mRNA‐type vaccines is scant, however. We herein report two similar cases of cutaneous adverse drug reactions (ADR) mimicking Rowell’s syndrome that occurred after the first dose of BNT162b2 and mRNA‐1273, respectively. Both patients achieved prompt clinical improvement with a short pulse of oral prednisolone and non‐steroidal inflammatory drugs. We suspect this phenomenon to occur in a timeframe of 7–14 days after vaccination due to an interferon‐γ‐driven shift towards type I immunity in susceptible individuals. As rheumatic patients were excluded from phase III clinical trials and as most countries prioritized the elderly population to receive the vaccinations first, cutaneous ADR might become more frequent once the younger part of the population is vaccinated over the course of 2021. Atypical cutaneous ADR might be misinterpreted or overlooked by non‐dermatologists. Further studies are required to determine the best suitable vaccine types for individual groups of patients. with immunological findings of speckled antinuclear antibodies (ANA), anti-La/anti-SS-B antibodies, and detection of rheumatoid factor (RF). Due to its rarity, this entity is still a matter of debate. New diagnostic criteria were proposed 20 years ago and presupposed presence of all indispensable major criteria (lupus erythematosus including CLE, EM-like lesions with or without involvement of mucous membranes and speckled ANA) and at least one minor criteria (chilblains, anti-Ro/anti-SSA or anti-La/anti-SSB antibodies, RF). 6 We herein report two patients who experienced clinical findings mimicking RS in the course of COVID-19 mRNA vaccination and speculate about the pathophysiological background in light of the available data. A 41-year-old male patient had been on daily medication with hydroxychloroquine 200 mg p.o. and prednisolone 5 mg p.o. for 4 years due to rheumatic joint stiffness as well as Raynaud's syndrome and puffy fingers. As serology revealed a high titer of ANA (1:10 240) and anti-U1-RNP antibodies, he was diagnosed with mixed connective tissue disease. He had never experienced typical symptoms of CLE and was healthy otherwise, being a non-smoker without any other comedication. His family history included neither skin nor rheumatic A 22-year-old female patient, who was healthy except for hypothy- There is a theoretical vaccine-derived risk for relapse or incitement of autoimmune diseases as a result of robust effects on the innate immune system. mRNA represent danger-associated molecules which activate Toll-like receptors resulting in type I IFN production. 7 There is preliminary evidence that mRNA vaccines may trigger cutaneous lesions of CLE, which is a somewhat expected finding considering the IFN-driven inflammatory loop of the disease. 8 We screened the literature for cutaneous ADR to BNT162b2 and mRNA-1273 vaccines (Table 1) and found considerable heterogeneity in the reported data, which include registry studies, summaries of pharmacovigilance reports, and case series. The most frequent findings are localized reactions including erythema and swelling which may be divided into early and late reactions ( Figure 2 ). This is in line with the safety profile obtained from the clinical development programs of the respective agents. 9 It will be important to collect further data to conclude whether reactions to mRNA vaccines deviate from other vaccine types and if they impose a larger risk to patients with pre-existing autoimmune disease including dermatoses and connective tissue diseases. 10 As dermatologists are approached as a first instance by patients experiencing cutaneous ADR, they hold a key position in patient education and management. 11 We thank the patients for granting permission of publishing their case details and photographs. The authors have been advisors and/or received speakers' honoraria or travel expense reimbursements and/or received grants and/or par- is founder of the non-profit biotech company "Davos Biosciences" within the International Kühne-Foundation. The remaining authors declare no conflict of interest Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine Prompt onset of Rowell's syndrome following the first BNT162b2 SARS-CoV-2 vaccination Redefining Rowell's syndrome SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: Version 1 COVID-19 vaccines: modes of immune activation and future challenges Coronavirus vaccination adverse reactions and the role of the dermatologist Adverse reactions following the first dose of ChAdOx1 nCoV-19 vaccine and BNT162b2 vaccine for healthcare workers in South Korea Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 Vaccine: an Italian single-centre case series Cutaneous adverse reactions after m-RNA COVID-19 vaccine: early reports from Northeast Italy Preliminary evidence on the safety profile of BNT162b2 (Comirnaty): new insights from data analysis in EudraVigilance and adverse reaction reports from an Italian health facility Rowell's syndrome in the course of coronavirus disease 2019 mRNA vaccines: An overlooked phenomenon?